Yan Wanyun, Chen Huiying, Lin Xiaoyu, Zhou Ruifa, Zhao Feng, Su Jiping
Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Front Endocrinol (Lausanne). 2025 Jan 15;15:1514268. doi: 10.3389/fendo.2024.1514268. eCollection 2024.
Primary squamous cell carcinoma of the thyroid (PSCCT) has recently been reclassified as a morphologic pattern of anaplastic thyroid carcinoma (ATC). Consequently, PSCCT and squamous cell carcinoma with papillary thyroid carcinoma (SCC-PTC) were categorized as ATC. However, in terms of clinical characteristics and overall prognosis, whether PSCCT is similar to SCC-PTC has yet to be sufficiently investigated. Therefore, this study aimed to elucidate the differences and similarities between PSCCT and SCC-PTC regarding clinicopathological characteristics and prognosis.
We retrospectively reviewed the medical records of patients with squamous cell carcinoma of the thyroid in our institution from December 2009 to December 2020. In addition, the publications in CNKI, Wanfang, VIP, PubMed, Embase, Web of Science, and ProQuest databases were systematically searched to collect patient information. According to pathological diagnosis, patients were divided into the PSCCT and SCC-PTC groups, and compared their clinical characteristics, treatment, and prognosis, respectively.
308 patients in the PSCCT group and 60 patients in the SCC-PTC group were enrolled in the study. There were significant differences in gender, age, T stage, N stage, M stage, symptoms at diagnosis, and TTF-1 expression between the two groups. Patients in the SCC-PTC group with more frequent radioactive iodine therapy, surgery, and less frequent radiotherapy than PSCCT. In addition, PSCCT and SCC-PTC also demonstrated similarities in tracheal invasion, esophageal invasion, CK5/6 expression, TG expression, P53 expression, and chemotherapy frequency. The 3-year overall survival rate of PSCCT (19.1%) was lower than that of SCC-PTC (34.6%). The prognostic factors were different between the two groups. Multivariable analysis shows that the N stage, M stage, radiotherapy, and tracheal invasion were related to the prognosis of PSCCT, while only the T stage was associated with the prognosis in SCC-PTC.
Clinicopathological characteristics and prognosis were not identical in patients with SCC-PTC and PSCCT. These findings indicated that different clinical treatment and management plans are required for patients with these two types of thyroid cancer.
甲状腺原发性鳞状细胞癌（PSCCT）最近被重新分类为间变性甲状腺癌（ATC）的一种形态学模式。因此，PSCCT和伴有甲状腺乳头状癌的鳞状细胞癌（SCC-PTC）被归类为ATC。然而，就临床特征和总体预后而言，PSCCT是否与SCC-PTC相似尚未得到充分研究。因此，本研究旨在阐明PSCCT和SCC-PTC在临床病理特征和预后方面的差异和相似之处。
我们回顾性分析了2009年12月至2020年12月我院甲状腺鳞状细胞癌患者的病历。此外，系统检索了中国知网、万方、维普、PubMed、Embase、Web of Science和ProQuest数据库中的文献以收集患者信息。根据病理诊断，将患者分为PSCCT组和SCC-PTC组，并分别比较他们的临床特征、治疗情况和预后。
本研究纳入了308例PSCCT组患者和60例SCC-PTC组患者。两组在性别、年龄、T分期、N分期、M分期、诊断时症状和TTF-1表达方面存在显著差异。SCC-PTC组患者接受放射性碘治疗、手术的频率高于PSCCT组，而接受放疗的频率低于PSCCT组。此外，PSCCT和SCC-PTC在气管侵犯、食管侵犯、CK5/6表达、TG表达、P53表达和化疗频率方面也表现出相似性。PSCCT的3年总生存率（19.1%）低于SCC-PTC（34.6%）。两组的预后因素不同。多变量分析显示，N分期、M分期、放疗和气管侵犯与PSCCT的预后相关，而在SCC-PTC中只有T分期与预后相关。
SCC-PTC和PSCCT患者的临床病理特征和预后并不相同。这些发现表明，这两种类型的甲状腺癌患者需要不同的临床治疗和管理方案。
